News in Adjuvant Therapy of Non-seminomatous Germ Cell Testicular Tumors of Stage I
Authors:
T. Pokrivčák; R. Lakomý; R. Vyzula
Authors place of work:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in the journal:
Klin Onkol 2016; 29(2): 107-110
Category:
Review
doi:
https://doi.org/10.14735/amko2016107
Summary
Thanks to a multidisciplinary approach, testicular germinative tumors are now assigned to a group of highly curable oncologic diseases with favorable prognoses. Despite the gradual increase in the incidence of this type of cancer in recent years, mortality remains low. Yet, guidelines for postoperative treatment of stage I non-seminomatous germ cell testicular tumors remain inconsistent due to the low number of randomized studies. The probability of relapse is strongly associated with the occurrence of lymphangiogenesis. The period after primarily orchiectomy can be utilized for close monitoring, cisplatin-based adjuvant chemotherapy, or retroperitoneal lymphadenectomy. All variants of therapy offer a cure rate of about 99 %. The use of adjuvant chemotherapy, as well as retroperitoneal lymph node dissection, is associated with acute and late adverse effects. The effort to minimize side effects with preserving the lowest number of relapses resulted in the need for comparing the number of chemotherapy cycles and chemotherapy vs. retroperitoneal lymphadenectomy. The aim of this review is to evaluate the different treatment modalities for stage I testicular germ cell tumors with respect to their efficacy and toxicity.
Key words:
non-seminomatous germ cell tumors – adjuvant chemotherapy – retroperitoneal lymph node dissection – surveillance
This work was supported by MH CZ – RVO (MMCI, 00209805).
The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.
The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
Submitted:
8. 6. 2015
Accepted:
17. 1. 2016
Zdroje
1. Dusek L, Muzik J, Maluskova D et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2014; 27(6): 406– 423. doi: 10.14735/amko2014406.
2. Pont J, Albrecht W, Postner G et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14(2): 441– 448.
3. Kollmannsberger C, Moore C, Chi KN et al. Non-risk-adapted surveillance for patients with stage Inonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010; 21(6): 1296– 1301. doi: 10.1093/annonc/mdp473.
4. Divrik RT, Akdoğan B, Ozen H et al. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors – is shift to risk adapted policy justified? J Urol 2006; 176(4): 1424– 1430.
5. Tandstad T, Ståhl O, Håkansson U et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol 2014; 25(11): 2167– 2172. doi: 10.1093/annonc/mdu375.
6. Oldenburg J, Aparicio J, Beyer J et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage Itesticular cancer. Ann Oncol 2015; 26(5): 833– 838. doi: 10.1093/annonc/mdu514.
7. Herr HW, Sheinfeld J, Puc HS et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997; 157(3): 860– 862.
8. Kollmannsberger C, Beyer J, Droz JP et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16(10): 3386– 3391.
9. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130(4): 1076– 1088.
10. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003; 63(15): 1565– 1577.
11. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160(4): 1347– 1352.
12. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120(2): 617– 624.
13. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18(8): 1725– 1732.
14. Petersen PM, Hansen SW, Giwercman A et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994; 5(4): 355– 358.
15. De Santis M, Bachner M, Scholz M et al. Late toxicity of two cycles PEB (cisplatin, etoposide, bleomycin) in the management of clinical stage I nonseminomatous germ cell tumors (NSGCT) of the testis: 20-year experience of the Vienna Testicular Tumor Study Group (VTTSG). In: Meeting Proceedings Genitourinary Cancers Symposium 2009: abstr. 234.
16. Westermann DH, Schefer H, Thalmann GN et al. Long-term follow-up results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 2008; 179(1): 163– 166.
17. Brydøy M, Fosså SD, Klepp O et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 2010; 58(1): 134– 141. doi: 10.1016/ j.eururo.2010.03.041.
18. Albers P, Siener R, Krege S et al. Randomized phase IIItrial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/ 94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26(18): 2966– 2972.
19. Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21(8): 1505– 1512.
20. Uroweb.org [homepage on the Internet]. Oncology guidelines. Guidelines on testicular cancer. European Association od Urology, 2015, [cited 2015 June 12]. Available from: https://uroweb.org/individual-guidelines/oncology-guidelines/.
21. Zhoubný novotvar varlete (C62). In: Modrá kniha České onkologické společnosti [online]. Platnost od 1. 3. 2015. 20. vyd. Brno: Masarykův onkologický ústav 2015: 126– 130. [citováno 12. června 2015]. Dostupné z: http://www.linkos.cz/informace-pro-praxi/modra-kniha/.
22. Travis LB, Fosså SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97(18): 1354– 1365.
23. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25(28): 4370– 4378.
24. Haugnes HS, Bosl GJ, Boer H et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30(30): 3752– 3763. doi: 10.1200/ JCO.2012.43.4431.
25. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21(8): 1513– 1523.
26. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23(16): 3718– 3725.
27. Nord C, Bjøro T, Ellingsen D et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003; 44(3): 322– 328.
28. Orre IJ, Murison R, Dahl AA et al. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun 2009; 23(6): 868– 874. doi: 10.1016/ j.bbi.2009.04.003.
29. Richiardi L, Bellocco R, Adami HO et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. Cancer Epidemiol Biomarkers Prev 2004; 13(12): 2157– 2166.
30. Nichols CR, Roth B, Albers P et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 2013; 31(28): 3490– 3493. doi: 10.1200/ JCO.2012.47.6010.
31. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14(4): 1106– 1113.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2016 Číslo 2
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Extravasation of Cytostatic Drugs – Prevention and Best Practices
- Anticancer Effect of Fish Oil – a Fable or the Truth?
- Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma – a Case Study